CX Institutional
REGN icon

CX Institutional’s Regeneron Pharmaceuticals REGN Stock Holding History

CX Institutional’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$380K Buy
501
+116
+30% +$87.7K 0.01% 542
2026
Q2 		$240K Sell
385
-1
-0.3% -$681 0.01% 700
2026
Q1 		$298K Buy
386
+12
+3% +$9.19K 0.01% 608
2025
Q4 		$289K Sell
374
-7
-2% -$4.75K 0.01% 594
2025
Q3 		$214K Buy
381
+79
+26% +$44.7K 0.01% 674
2025
Q2 		$159K Buy
302
+22
+8% +$12.3K 0.01% 688
2025
Q1 		$178K Sell
280
-18
-6% -$12.4K 0.01% 630
2024
Q4 		$212K Sell
298
-11
-4% -$9.23K 0.01% 507
2024
Q3 		$325K Buy
309
+7
+2% +$7.79K 0.01% 450
2024
Q2 		$317K Buy
302
+2
+0.7% +$1.94K 0.01% 449
2024
Q1 		$289K Sell
300
-15
-5% -$14.3K 0.01% 465
2023
Q4 		$277K Buy
315
+4
+1% +$3.29K 0.01% 425
2023
Q3 		$256K Buy
311
+30
+11% +$23.6K 0.01% 433
2023
Q2 		$202K Sell
281
-18
-6% -$13.9K 0.01% 501
2023
Q1 		$246K Buy
299
+12
+4% +$9.05K 0.01% 439
2022
Q4 		$207K Buy
+287
New +$212K 0.01% 490
2022
Q3 		– Sell
-154
Closed -$91K – 986
2022
Q2 		$91K Buy
+154
New +$100K 0.01% 561
2021
Q4 		– Sell
-133
Closed -$80K – 784
2021
Q3 		$80K Sell
133
-5
-4% -$3.1K 0.01% 489
2021
Q2 		$77K Buy
138
+53
+62% +$26.9K 0.01% 487
2021
Q1 		$40K Buy
85
+6
+8% +$2.92K ﹤0.01% 538
2020
Q4 		$38K Sell
79
-2
-2% -$1.08K ﹤0.01% 493
2020
Q3 		$45K Buy
81
+1
+1% +$606 ﹤0.01% 398
2020
Q2 		$50K Buy
80
+19
+31% +$10.8K 0.01% 339
2020
Q1 		$30K Buy
61
+36
+144% +$14.8K ﹤0.01% 340
2019
Q4 		$9K Hold
25
– – ﹤0.01% 445
2019
Q3 		$7K Sell
25
-3
-11% -$888 ﹤0.01% 521
2019
Q2 		$9K Buy
28
+2
+8% +$666 ﹤0.01% 509
2019
Q1 		$11K Buy
26
+22
+550% +$9.06K ﹤0.01% 450
2018
Q4 		$1K Buy
+4
New +$1.46K ﹤0.01% 508

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Vest Financial
Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
Atwood & Palmer
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Loring Wolcott & Coolidge Fiduciary Advisors
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.8B AUM 9.05% 1-Year Est. Return
LMCG Investments
LMCG Investments Boston, Massachusetts $1.86B AUM 40.01% 1-Year Est. Return

CX Institutional's REGN Position: Q3 2026 in Review

CX Institutional increased its Regeneron Pharmaceuticals (REGN) stake by 30% in Q3 2026, buying an estimated $87.7K and bringing the position to 501 shares worth $380K. The position accounts for 0.01% of the portfolio, ranked #542.

CX Institutional first reported a position in REGN in Q4 2018 and has held it in 29 quarters since. 333 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • CX Institutional held 501 shares of Regeneron Pharmaceuticals worth $380K as of Q3 2026.
  • CX Institutional bought 116 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $87.7K.
  • Regeneron Pharmaceuticals made up 0.01% of CX Institutional's portfolio in Q3 2026, its #542 holding.
  • CX Institutional first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • 333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.